BALL BRYAN 4
4 · Whitehawk Therapeutics, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Whitehawk Therapeutics (WHWK) CTO/SVP Bryan Ball Exercises Options, Receives RSUs
What Happened Bryan Ball — Chief Technical Operations Officer and SVP, Manufacturing Operations — reported transactions on Apr 1, 2026. The Form 4 shows an exercise/conversion of 366,532 derivative securities (code M), a corresponding disposition of 366,532 derivative shares at $0.00, and a grant/acquisition of 250,058 restricted stock units (RSUs) at $0.00. The filing records no cash proceeds for the disposed derivative shares.
Key Details
- Transaction date: April 1, 2026. Filing date (Accession): April 3, 2026 (timely).
- Exercise/Conversion (M): 366,532 shares acquired (price listed as N/A).
- Disposal (M): 366,532 shares disposed @ $0.00 (reported as derivative disposal; $0 proceeds).
- Grant/Award (A): 250,058 RSUs @ $0.00 (no cash paid).
- Shares owned after the transactions: not disclosed in this filing.
- Footnotes:
- F1: Each RSU represents a contingent right to one share of common stock.
- F2: The 250,058 RSUs vest 100% on the one-year anniversary of the Vesting Commencement Date (VCD = April 1, 2025) — i.e., subject to continued service, they vest on April 1, 2026.
- F3: Option vesting schedule referenced (VCD = April 1, 2026): 25% after one year, then monthly vesting over four years (applies to option awards noted).
- No 10b5-1 plan, tax-withholding sale, or sale proceeds are indicated in the reported entries.
Context RSUs are a grant that convert to shares if vesting conditions are met; here the RSUs are subject to a one-year cliff (vesting date Apr 1, 2026) per the filing. The report shows derivative exercise/conversion activity and a grant rather than an open-market buy or a standard cash sale; because the filing reports $0.00 for disposed derivative shares and N/A for the exercise price, the document does not show any cash proceeds to the insider. This filing is informational about equity-based compensation and conversions rather than a clear cash purchase or sale on the open market.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-04-01+366,532→ 572,551 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-04-01−366,532→ 0 total→ Common Stock (366,532 underlying) - Award
Stock Option (right to buy)
[F3]2026-04-01+250,058→ 250,058 totalExercise: $3.54Exp: 2036-04-01→ Common Stock (250,058 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
- [F2]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
- [F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.